CAR- T and cellular genetics therapies are too costly

.Nature Medicine, Released online: 04 September 2024 doi:10.1038/ s41591-024-03231-zPoint-of-care manufacturing as well as technology transfer can easily supply cellular gene treatments at a cost effective price to clients around the planet.